Benoît Tyl1, José Lopez Sendon2, Jeffrey S Borer3,4, Esteban Lopez De Sa5, Guy Lerebours6, Claire Varin1, Aurélie De Montigny7, Matthieu Pannaux7, Michel Komajda8. 1. CardioVascular & Metabolic Disease Center for Therapeutic Innovation, Institut de Recherches Internationales Servier, Suresnes, France. (B.T., C.V.). 2. Cardiology Department, University Hospital La Paz, UAM, IdiPaz, CiberCV, Madrid, Spain. (J.L.S.). 3. College of Medicine, School of Public Health, SUNY Downstate Medical Center, Brooklyn, New York (J.S.B.). 4. Weill Cornell Medicine, New York, NY (J.S.B.). 5. Acute Cardiac Care Unit, University Hospital La Paz, UAM, IdiPaz, CiberCV, Madrid, Spain. (E.L.D.S.). 6. Health Value 92, Levallois-Perret, France (G.L.). 7. Center of Excellence Methodology and Valorisation of Data, Institut de Recherches Internationales Servier, Suresnes, France. (A.D.M., M.P.). 8. Department of Cardiology, Hospital Saint Joseph, Paris, France (M.K.).
Abstract
BACKGROUND: The usefulness of adjudication by central end point committees (CECs) is poorly assessed in heart failure (HF) trials. We aimed to assess its impact on the outcome of the SHIFT trial (Systolic HF Treatment With the If Inhibitor Ivabradine Trial). METHODS: SHIFT was a randomized placebo-controlled trial investigating the effect of ivabradine in 6505 HF patients with reduced ejection fraction. Prespecified end points, reported by investigators (all cardiologists) using specific case report form pages, included all-cause and specific causes of deaths and hospitalizations. The primary end point was a composite of cardiovascular deaths or hospitalizations for worsening HF. We compared the adjudication of prespecified end points made by investigators and by the CEC. RESULTS: Investigators identified 7529 prespecified end points, 6793 of which were confirmed by the CEC: 98.1% of cardiovascular deaths, 88.6% of all hospitalizations, and 84.4% of hospitalizations for worsening HF. These differences had no meaningful impact on the study results; hazard ratio for the primary composite end point: investigators, 0.83 (95% CI, 0.76-0.91) versus CEC, 0.82 (95% CI, 0.75-0.90), with similar results for each component of the primary end point (hazard ratio of 0.92 versus 0.91 for cardiovascular death and 0.78 versus 0.74 for hospitalization for worsening HF). CONCLUSIONS: Central adjudication by a CEC in the SHIFT study confirmed most of cardiovascular deaths and worsening HF hospitalizations assessed by cardiologists and did not result in a significant change of the final result as compared to investigator judgment. In this context, the benefits of CEC in blinded HF trials should be reconsidered. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02441218. URL: http://www.isrctn.com/ISRCTN70429960; Unique identifier: ISRCTN70429960.
RCT Entities:
BACKGROUND: The usefulness of adjudication by central end point committees (CECs) is poorly assessed in heart failure (HF) trials. We aimed to assess its impact on the outcome of the SHIFT trial (Systolic HF Treatment With the If Inhibitor Ivabradine Trial). METHODS: SHIFT was a randomized placebo-controlled trial investigating the effect of ivabradine in 6505 HF patients with reduced ejection fraction. Prespecified end points, reported by investigators (all cardiologists) using specific case report form pages, included all-cause and specific causes of deaths and hospitalizations. The primary end point was a composite of cardiovascular deaths or hospitalizations for worsening HF. We compared the adjudication of prespecified end points made by investigators and by the CEC. RESULTS: Investigators identified 7529 prespecified end points, 6793 of which were confirmed by the CEC: 98.1% of cardiovascular deaths, 88.6% of all hospitalizations, and 84.4% of hospitalizations for worsening HF. These differences had no meaningful impact on the study results; hazard ratio for the primary composite end point: investigators, 0.83 (95% CI, 0.76-0.91) versus CEC, 0.82 (95% CI, 0.75-0.90), with similar results for each component of the primary end point (hazard ratio of 0.92 versus 0.91 for cardiovascular death and 0.78 versus 0.74 for hospitalization for worsening HF). CONCLUSIONS: Central adjudication by a CEC in the SHIFT study confirmed most of cardiovascular deaths and worsening HF hospitalizations assessed by cardiologists and did not result in a significant change of the final result as compared to investigator judgment. In this context, the benefits of CEC in blinded HF trials should be reconsidered. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02441218. URL: http://www.isrctn.com/ISRCTN70429960; Unique identifier: ISRCTN70429960.
Authors: Milton Packer; Javed Butler; Faiez Zannad; Gerasimos Filippatos; Joao Pedro Ferreira; Stuart J Pocock; Peter Carson; Inder Anand; Wolfram Doehner; Markus Haass; Michel Komajda; Alan Miller; Steen Pehrson; John R Teerlink; Sven Schnaidt; Cordula Zeller; Janet M Schnee; Stefan D Anker Journal: Circulation Date: 2021-08-29 Impact factor: 29.690
Authors: Niklas Dyrby Johansen; Daniel Modin; Joshua Nealon; Sandrine Samson; Camille Salamand; Carsten Schade Larsen; Brian L Claggett; Scott D Solomon; Martin J Landray; Gunnar H Gislason; Lars Køber; Jens Ulrik Stæhr Jensen; Pradeesh Sivapalan; Lasse Skafte Vestergaard; Palle Valentiner-Branth; Tyra Grove Krause; Tor Biering-Sørensen Journal: Pilot Feasibility Stud Date: 2022-04-21
Authors: Anna Meta Dyrvig Kristensen; Manan Pareek; Kristian Hay Kragholm; Thomas Steen Gyldenstierne Sehested; Michael Hecht Olsen; Eva Bossano Prescott Journal: Cardiology Date: 2022-05-10 Impact factor: 2.342
Authors: Milton Packer; Stefan D Anker; Javed Butler; Gerasimos Filippatos; João Pedro Ferreira; Stuart J Pocock; Peter Carson; Inder Anand; Wolfram Doehner; Markus Haass; Michel Komajda; Alan Miller; Steen Pehrson; John R Teerlink; Martina Brueckmann; Waheed Jamal; Cordula Zeller; Sven Schnaidt; Faiez Zannad Journal: Circulation Date: 2020-10-21 Impact factor: 29.690
Authors: Jakub Lagan; Erik B Schelbert; Josephine H Naish; Jørgen Vestbo; Christien Fortune; Joshua Bradley; John Belcher; Edward Hearne; Foluwakemi Ogunyemi; Richard Timoney; Daniel Prescott; Hamish D C Bain; Tasneem Bangi; Mahvash Zaman; Christopher Wong; Anthony Ashworth; Helen Thorpe; Robin Egdell; Jerome McIntosh; Bruce R Irwin; David Clark; Graham Devereux; Jennifer K Quint; Richard Barraclough; Matthias Schmitt; Christopher A Miller Journal: JACC Cardiovasc Imaging Date: 2021-05-19